Biomea Fusion has opened enrollment for its COVALENT-212 trial of icovamenib in type 2 diabetes. The study targets adults 18-70 on stable semaglutide doses, fol

Biomea Fusion has opened enrollment for its COVALENT-212 trial of icovamenib in type 2 diabetes. The study targets adults 18-70 on stable semaglutide doses, following earlier company data showing HbA1c improvements sustained beyond 12 weeks.